195 related articles for article (PubMed ID: 8359853)
1. Systemic and gastrointestinal candidiasis of infant mice as model for antifungal therapy.
Ponnuvel KM; Rama CP; Menon T
Indian J Exp Biol; 1993 May; 31(5):450-2. PubMed ID: 8359853
[TBL] [Abstract][Full Text] [Related]
2. Pathogenesis and management of Candida infection syndromes in non-neutropenic patients.
Solomkin JS
New Horiz; 1993 May; 1(2):202-13. PubMed ID: 7922404
[TBL] [Abstract][Full Text] [Related]
3. Activities of flucytosine, fluconazole, amphotericin B, and micafungin in a murine model of disseminated infection by Candida glabrata.
Mariné M; Serena C; Fernández-Torres B; Pastor FJ; Guarro J
Antimicrob Agents Chemother; 2005 Nov; 49(11):4757-9. PubMed ID: 16251323
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of aminocandin in the treatment of immunocompetent mice with haematogenously disseminated fluconazole-resistant candidiasis.
Ghannoum MA; Kim HG; Long L
J Antimicrob Chemother; 2007 Mar; 59(3):556-9. PubMed ID: 17242032
[TBL] [Abstract][Full Text] [Related]
5. The comparative efficacy of cilofungin, fluconazole and amphotericin B in disseminated Candida tropicalis infection in neutropenic mice.
Fong IW; Bannatyne RM; Cheng PC
Clin Invest Med; 1992 Oct; 15(5):434-9. PubMed ID: 1458716
[TBL] [Abstract][Full Text] [Related]
6. Activity of aminocandin (IP960) compared with amphotericin B and fluconazole in a neutropenic murine model of disseminated infection caused by a fluconazole-resistant strain of Candida tropicalis.
Warn PA; Sharp A; Morrissey G; Denning DW
J Antimicrob Chemother; 2005 Sep; 56(3):590-3. PubMed ID: 16046462
[TBL] [Abstract][Full Text] [Related]
7. Combined antifungal therapy in a murine infection by Candida glabrata.
Mariné M; Serena C; Pastor FJ; Guarro J
J Antimicrob Chemother; 2006 Dec; 58(6):1295-8. PubMed ID: 17012301
[TBL] [Abstract][Full Text] [Related]
8. Fluconazole resistance of Candida krusei.
Manso E; Montillo M; Discepoli G; Leoni P
Boll Ist Sieroter Milan; 1991-1992; 70(1-2):527-9. PubMed ID: 1670057
[TBL] [Abstract][Full Text] [Related]
9. [Current treatment of candidemia in non-neutropenic patients. Amphotericin B or fluconazole? A retrospective study of 62 consecutive patients].
Cobo Reinoso P; Aguado García JM; Lumbreras Bermejo C; Pérez Vela JL; Caballero Cubedo R; Sanz Sanz F; Noriega Rodríguez AR
Rev Clin Esp; 1997 Dec; 197(12):799-803. PubMed ID: 9477669
[TBL] [Abstract][Full Text] [Related]
10. A randomized study comparing fluconazole with amphotericin B/5-flucytosine for the treatment of systemic Candida infections in intensive care patients.
Abele-Horn M; Kopp A; Sternberg U; Ohly A; Dauber A; Russwurm W; Büchinger W; Nagengast O; Emmerling P
Infection; 1996; 24(6):426-32. PubMed ID: 9007589
[TBL] [Abstract][Full Text] [Related]
11. [Comparative study of the therapy of Candida esophagitis in HIV-1-infected patients with fluconazole or amphotericin B and flucytosine].
Brockmeyer NH; Hantschke D; Olbricht T; Hengge UA; Goos M
Mycoses; 1991; 34 Suppl 1():83-6. PubMed ID: 1818270
[TBL] [Abstract][Full Text] [Related]
12. The fluconazole era: management of hematogenously disseminated candidiasis in the nonneutropenic patient.
Kramer KM; Skaar DJ; Ackerman BH
Pharmacotherapy; 1997; 17(3):538-48. PubMed ID: 9165556
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the efficacy of cilofungin, fluconazole and amphotericin B in the treatment of systemic Candida albicans infection in the neutropenic mouse.
Bannatyne RM; Cheng PC; Fong IW
Infection; 1992; 20(3):168-70. PubMed ID: 1644494
[TBL] [Abstract][Full Text] [Related]
14. The prophylactic effectiveness of various antifungal agents against the progression of trichosporonosis fungemia to disseminated disease in a neutropenic mouse model.
Tokimatsu I; Kushima H; Hashinaga K; Umeki K; Ohama M; Ishii H; Kishi K; Hiramatsu K; Kadota J
Int J Antimicrob Agents; 2007 Jan; 29(1):84-8. PubMed ID: 17189098
[TBL] [Abstract][Full Text] [Related]
15. Fluconazole plus amphotericin B combinations are not contraindicated and may add benefit for the treatment of candidemia.
Odds FC
Clin Infect Dis; 2003 May; 36(10):1229-31. PubMed ID: 12746766
[No Abstract] [Full Text] [Related]
16. Candida lusitaniae: a cause of breakthrough fungemia in cancer patients.
Minari A; Hachem R; Raad I
Clin Infect Dis; 2001 Jan; 32(2):186-90. PubMed ID: 11170906
[TBL] [Abstract][Full Text] [Related]
17. Epidemiology and treatment of hematogenous candidiasis: a Brazilian perspective.
Colombo AL
Braz J Infect Dis; 2000 Jun; 4(3):113-8. PubMed ID: 10934493
[TBL] [Abstract][Full Text] [Related]
18. Successful treatment of a Candida albicans sepsis with a combination of flucytosine and fluconazole.
Scheven M; Jünemann K; Schramm H; Hühn W
Mycoses; 1992; 35(11-12):315-6. PubMed ID: 1302806
[TBL] [Abstract][Full Text] [Related]
19. Alternative dosing regimens of liposomal amphotericin B (AmBisome) effective in treating murine systemic candidiasis.
Adler-Moore JP; Olson JA; Proffitt RT
J Antimicrob Chemother; 2004 Dec; 54(6):1096-102. PubMed ID: 15509617
[TBL] [Abstract][Full Text] [Related]
20. Candida albicans brain abscesses in a premature infant treated with amphotericin B, flucytosine and fluconazole.
Kamitsuka MD; Nugent NA; Conrad PD; Swanson TN
Pediatr Infect Dis J; 1995 Apr; 14(4):329-31. PubMed ID: 7603822
[No Abstract] [Full Text] [Related]
[Next] [New Search]
